ArticleJournal of visualized experiments : JoVE2017
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein.
Article in Journal of visualized experiments : JoVE, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- The impact of aerobic and isometric exercise on different measures of dysfunctional high-density lipoprotein in patients with hypertension.European journal of preventive cardiology · 2019Trial
- Early Emergence of HDL Oxidation Across the Body Mass Index Spectrum in Patients with Suspected Coronary Artery Disease.International journal of molecular sciences · 2026Article
- Reduced antioxidant high-density lipoprotein function in heart failure with preserved ejection fraction.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Observational
- Oxidized high-density lipoprotein associates with cardiometabolic dysfunction in coronary artery disease and acute coronary syndrome.Journal of internal medicine · 2025Article
- Effect of Dietary PUFAs and Antioxidants on Antioxidant and Anti-Inflammatory Functions of HDL in a Cohort of Women.Antioxidants (Basel, Switzerland) · 2025Article
- Reduced high-density lipoprotein antioxidant function in patients with coronary artery disease and acute coronary syndrome.JCI insight · 2025Article
- Healthier Lipid Profiles of Japanese Adults, Especially in Women with Elevated High-Density Lipoprotein Cholesterol (HDL-C), Are Associated with Low HDL-C Peroxide Content.Antioxidants (Basel, Switzerland) · 2024Article
- Oxidized high-density lipoprotein associates with atrial fibrillation.Heart rhythm · 2024Article
- Dysfunctional high-density lipoprotein in chronic inflammatory rheumatic diseases.Therapeutic advances in musculoskeletal disease · 2023Article
- Quality by Design Approach in Liposomal Formulations: Robust Product Development.Molecules (Basel, Switzerland) · 2022Review
- Race and sex differences in HDL peroxide content among American adults with and without type 2 diabetes.Lipids in health and disease · 2022Article
- Changing Perspectives on HDL: From Simple Quantity Measurements to Functional Quality Assessment.Journal of lipids · 2021Review
- High-density lipoprotein lipid peroxidation as a molecular signature of the risk for developing cardiovascular disease: Results from MASHAD cohort.Journal of cellular physiology · 2019Article
- Human T lymphotropic virus type 1 and risk of cardiovascular disease: High-density lipoprotein dysfunction versus serum HDL-C concentrations.BioFactors (Oxford, England) · 2019Article
- Dysfunctional high-density lipoprotein predicts survival, renal recovery and the need for kidney replacement therapy in acute kidney injury.Journal of circulating biomarkersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
Low high-density lipoprotein cholesterol (HDL-C) levels are one of the most powerful independent negative predictors of atherosclerotic cardiovascular disease (CVD). The structure and function of HDL rather than HDL-C may more accurately predict atherosclerosis. Several HDL protein and lipid compositional changes that impair HDL function occur in inflammatory states such as atherosclerosis. HDL function is usually determined by cell based assays such as cholesterol efflux assay but these assays have numerous drawbacks lack of standardization. Cell-free assays may give more robust measures of HDL function compared to cell-based assays. HDL oxidation impairs HDL function. HDL has a major role in lipid peroxide transport and high amount of lipid peroxides is related to abnormal HDL function. Lipid-probe interactions should be considered when interpreting the results of non-enzymatic fluorescence assays for measuring the lipid oxidative state. This motivated us to develop a cell-free biochemical enzymatic method to assess HDL lipid peroxide content (HDLox) that contributes to HDL dysfunction. This method is based on the enzyme horseradish peroxidase (HRP) and the fluorochrome Amplex Red that can quantify (without cholesterol oxidase) the lipid peroxide content per mg of HDL-C. Here a protocol is describedfor determination of HDL-lipid peroxidation using the fluorochrome reagent. Assay variability can be reduced by strict standardization of experimental conditions. Higher HDLox values are associated with reduced HDL antioxidant function. The readout of this assay is associated with readouts of validated cell-based assays, surrogate measures of cardiovascular disease, systemic inflammation, immune dysfunction, and associated cardiovascular and metabolic risk phenotypes. This technical approach is a robust method to assess HDL function in human disease where systemic inflammation, oxidative stress and oxidized lipids have a key role (such as atherosclerosis).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.